You are here: Home » Companies » News
Business Standard

Dr Reddy's launches stomach, esophagus problems treatment drug in US

The product is a therapeutic equivalent generic version of Prevacid SoluTab delayed release orally disintegrating tablets approved by the US Food and Drug Administration (USFDA)

Topics
Dr Reddys | USFDA | Pharmaceutical

Press Trust of India  |  New Delhi 

Dr Reddy's
In a regulatory filing, Dr Reddy''s laboratories announced launch of Lansoprazole DR (delayed release) orally disintegrating tablets.

Drug major Dr Reddy's Laboratories on Monday said it has launched Lansoprazole delayed release orally disintegrating tablets, used to treat certain stomach and esophagus problems , in the US market.

The product is a therapeutic equivalent generic version of Prevacid SoluTab delayed release orally disintegrating tablets approved by the US Food and Drug Administration (USFDA).

In a regulatory filing, Dr Reddy's laboratories announced launch of Lansoprazole DR (delayed release) orally disintegrating tablets.

Quoting IQVIA Health data, Dr Reddy's said the Prevacid brand and generic had US sales of approximately USD 87 million for the most recent 12 months ending in December 2020.

Dr Reddy's Lansoprazole DR orally disintegrating tablets are available in 15 mg and 30 mg tablets in unit-dose packages of 100.

Shares of Dr Reddy's Laboratories were trading 1.50 per cent lower at Rs 4,615 apiece on BSE.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, February 22 2021. 11:57 IST
RECOMMENDED FOR YOU
.